On this page ▾
We do not publish one number for Abbott India — and here is why.
Our engine has not published a single fair value for Abbott India, and the filed history it would rely on is incomplete in the data used for this page. Rather than print an unreliable number, the workings are shown instead.
- How it is valued: business by business, with no single blended figure.
- What the price assumes: 1% growth, against 8% the model takes from its own record.
- Biggest swing factor: Brand strength. Main risk: Price controls.
01Abbott's Indian pharma business
Abbott India is the listed Indian pharmaceutical arm of US-based Abbott Laboratories, which owns the majority. It sells branded medicines for thyroid (Thyronorm), women's health (Duphaston), gastrointestinal (Udiliv, Cremaffin), and consumer health (Digene).
It has no debt, a large cash balance and pays a large share of profit as dividends.
02What the market is assuming
Work backwards from today's share price and you can see what buyers are quietly taking for granted. Here is the growth that price implies for Abbott India, next to what the model assumes from the company's own record.
The further apart these two numbers are, the bigger the bet a buyer at today's price is making.
03Abbott India's record, in plain numbers
04How Abbott India gets valued — and why
Estimate withheld — the engine says so itselfThis is a group of businesses with different economics. A single discounted cash flow across all of them averages them into something that describes none of them, so our engine withholds a single blended fair value rather than publishing a number it cannot defend. The parts are valued separately instead.
05What decides Abbott India's value
Brand strength
Market-leading brands support pricing.
Chronic therapies
Thyroid and women's health give steady demand.
Consumer health
Over-the-counter brands like Digene add growth.
Dividends
High payouts return cash.
06What could go wrong
- Price controls. India's drug-price rules cap some products.
- Parent decisions. Product allocation and royalties are set by Abbott.
- The premium. A high valuation assumes steady growth.
07What the full Abbott India valuation shows
Sign in free to see the complete Abbott India valuation
- ✓The full model workings — and exactly where the model and the market part ways
- ✓Every assumption — growth, returns and cost of capital, with sources
- ✓Bull, base and bear cases — and exactly which assumptions move between them
- ✓Peer comparison — against Sun Pharma, Mankind Pharma and other drugmakers
- ✓Downloadable report — the full write-up, yours to keep
08Questions people ask about Abbott India
What are Abbott India's brands?
Thyronorm, Duphaston, Udiliv, Cremaffin and Digene among others.
Who owns Abbott India?
US-based Abbott Laboratories holds the majority.
Does Abbott India have debt?
No; it has a large cash balance.
Is Abbott India overvalued?
At ₹26,440 the market is pricing in roughly 1% sustained growth, against the ~8% its own record supports. That is less than it has delivered — on these numbers the market is asking the business for less than its own record, which usually means it doubts the record repeats.
What is the intrinsic value of Abbott India?
This business is a group of operations with different economics, so a single blended figure would describe none of them. The parts are valued separately and the breakdown is in the report, rather than one number that cannot be defended.